Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

(2012) G. L. Andriole et al.   JNCI-Journal of the National Cancer Institute

What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing?

(2010) Stacy Loeb et al.   JOURNAL OF CLINICAL ONCOLOGY

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

(2010) Jonas Hugosson et al.   LANCET ONCOLOGY

Can Prostate Specific Antigen Velocity Thresholds Decrease Insignificant Prostate Cancer Detection?

(2009) Stacy Loeb et al.   JOURNAL OF UROLOGY

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of the Prostate-Specific Antigen Test among U.S. Men: Findings from the 2005 National Health Interview Survey

(2008) L. E. Ross et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in Screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)

(2008) Tineke Wolters et al.   EUROPEAN UROLOGY

Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer

(2008) Andrew J. Vickers et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors

(2008) Martin G. Sanda et al.   NEW ENGLAND JOURNAL OF MEDICINE